New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 7, 2014
09:05 EDTBAX, HRCHill-Rom CFO Saccaro to leave company to re-join Baxter
Hill-Rom (HRC) said in a filing that on July 1, Jay Saccaro, CFO of the corporation, informed the Corporation that he was resigning to accept a position with his previous employer, Baxter International (BAX), as CFO-designate of the post-spin-off company. Saccaro ceased to be the principal financial officer of the corporation as of July 3. As of July 3, Michael Macek, the Vice President and Treasurer of the Corporation, assumed the additional duties of Interim CFO and become the principal financial officer of the corporation pending the search for Saccaro’s replacement. Macek was elected Treasurer in March 2011. Prior to such date, he held the position of Executive Director, Treasury for Hill-Rom since 2008, and a series of financial positions with Hill-Rom since 2005. He also served as the corporation’s Interim CFO from July 2013 through December 2013.
News For HRC;BAX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 20, 2015
09:02 EDTBAXBaxter receives FDA approval for PHOXILLUM solution
Subscribe for More Information
08:16 EDTBAXMerrimack data of Phase 3 MM-398 NAPOLI-1 study supports development programs
Merrimack Pharmaceuticals (MACK) announced that additional analyses were presented on January 16, 2015 from the Phase 3 NAPOLI-1 study of MM-398, also known as nal-IRI, in patients with metastatic pancreatic cancer previously treated with gemcitabine-based therapy. Merrimack and Baxter International's (BAX) biopharmaceutical business are collaborating on the development and commercialization of MM-398 outside of the United States and Taiwan. PharmaEngine holds the rights to commercialize MM-398 in Taiwan. Additionally, Merrimack presented preclinical and clinical data from studies of its investigational agents MM-141 and MM-151 in pancreatic and colorectal cancer, respectively. An investigator-sponsored study of MM-398 in colorectal cancer was also presented. The extended analyses for the global NAPOLI-1 Phase 3 trial presented at ASCO GI support the robustness of the overall survival benefit of MM-398 in combination with 5-fluorouracil, or 5-FU, and leucovorin presented in June 2014, at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer, or ESMO GI. The primary analysis, presented at ESMO GI, demonstrated a statistically significant advantage in overall survival with an unstratified hazard ratio of 0.67, and a median of 6.1 months for the combination of MM-398 plus 5-FU and leucovorin compared to 4.2 months in the control arm.
January 15, 2015
07:13 EDTHRCJPMorgan to hold a conference
Subscribe for More Information
January 14, 2015
16:09 EDTHRCHill-Rom sees Q1 revenue $465M, consensus $453.6M
Subscribe for More Information
09:06 EDTHRCHill-Rom named in antitrust lawsuit by University Hospital Services
Universal Hospital Services announced the filing of a lawsuit against Hill-Rom Holdings. The complaint alleges that Hill-Rom is violating federal and state antitrust laws by willfully and unlawfully engaging in a pattern of “exclusionary and predatory conduct” in order to “foreclose [market] competition.” The lawsuit, which was filed in the United States District Court for the Western District of Texas in San Antonio, seeks injunctive relief and treble damages, the amount of which will be determined at trial. The company says in its complaint that it filed the lawsuit “to preserve choice” in the medical equipment rental industry and to prevent Hill-Rom “from destroying competition in the industry by engaging in a variety of anti-competitive practices that have previously been subject to an injunction and resulted in the payment of over half a billion dollars by Hill-Rom to competitors, hospitals, and healthcare providers.”
06:21 EDTHRCHill-Rom accused of 'predatory' actions in new lawsuit, NY Post says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use